Jiangsu Hengrui Pharmaceuticals (SHA:600276) obtained drug registration from China's medical products regulator for its luzinuole sodium tablets.
The drug is used for gout with hyperuricemia, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 3% in recent trade.